Eledon Pharmaceuticals Inc. has announced that updated clinical data from its ongoing Phase 1b trial of tegoprubart, an anti-CD40L antibody, will be presented at the upcoming World Transplant Congress 2025 in San Francisco. The open-label study focuses on the prevention of rejection in patients undergoing kidney transplantation. The oral presentation, scheduled for August 6, 2025, will feature results from approximately 30 kidney transplant recipients and will be delivered by Dr. John Gill from the University of British Columbia. The presentation will be part of the session on "Kidney Novel Immunosuppressant Strategies." Additionally, Eledon will sponsor a satellite symposium at the congress and present new preclinical data on tegoprubart in a poster session. A copy of the oral presentation will be available on the company's website following the session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。